The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1738
September 29, 2025
View Complete Issue         Table of Contents 2019 
IV Meloxicam Returns for Treatment of Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
IV Meloxicam Returns for Treatment of Pain
September 29, 2025 (Issue: 1738)
The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with non-NSAID analgesics for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: IV Meloxicam Returns for Treatment of Pain
Article code: 1738b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.